Sandra M. Gaston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandra M. Gaston has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Adrian L. Breto
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3 shared publications - Alan Pollack
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3 shared publications - Isaac R. L. Xu
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3 shared publications - Oleksandr N. Kryvenko
Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
3 shared publications - Radka Stoyanova
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3 shared publications - Sanoj Punnen
Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3 shared publications
Latest Publications
- Open Access
- 14 March 2026
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 30 (3) , 441-461
Pre-analytical Best Practices for RNA Sequencing from Small Biopsies and Cytologic Specimens
RNA sequencing is becoming increasingly common in precision oncology, in both clinical and research settings, for transcriptome profiling, gene-fusion detection, and biomarker discovery. RNA-sequencing analysis of specimens obtained via minimally invasive procedures such as small biopsy, fine needle aspiration, and exfoliation offers a powerful method for analyzing gene expression patterns and detecting RNA-level changes associated with cancers that are either difficult to collect or require longitudinal sampling. However, pre-analytical factors (e.g., details of specimen collection, processing, and storage workflow) influence not only RNA-sequencing success rates but also the quality and accuracy of sequencing results, which may affect patient care and research progress. Minimally invasive specimens are associated with a unique set of pre-analytical challenges owing to their small size, limited RNA yield, and distinct workflows. To address the need for evidence-based guidance, this review by a working group of National Cancer Institute grantees and intramural and extramural researchers identifies pre-analytical best practices for minimally invasive specimens destined for RNA-sequencing analysis, based on the available literature and their collective experience. Strategies for assessing specimen adequacy and RNA quality, maximizing tumor content, and minimizing specimen loss and RNA degradation due to pre-analytical handling are specified for small tissue and cytology specimens. By integrating current evidence and institutional insights, this review provides a practical framework for enhancing RNA-sequencing reliability and reproducibility in both clinical and research workflows.
- 14 March 2026
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 30 (3) , 441-461
Open AccessPre-analytical Best Practices for RNA Sequencing from Small Biopsies and Cytologic Specimens
RNA sequencing is becoming increasingly common in precision oncology, in both clinical and research settings, for transcriptome profiling, gene-fusion detection, and biomarker discovery. RNA-sequencing analysis of specimens obtained via minimally invasive procedures such as small biopsy, fine needle aspiration, and exfoliation offers a powerful method for analyzing gene expression patterns and detecting RNA-level changes associated with cancers that are either difficult to collect or require longitudinal sampling. However, pre-analytical factors (e.g., details of specimen collection, processing, and storage workflow) influence not only RNA-sequencing success rates but also the quality and accuracy of sequencing results, which may affect patient care and research progress. Minimally invasive specimens are associated with a unique set of pre-analytical challenges owing to their small size, limited RNA yield, and distinct workflows. To address the need for evidence-based guidance, this review by a working group of National Cancer Institute grantees and intramural and extramural researchers identifies pre-analytical best practices for minimally invasive specimens destined for RNA-sequencing analysis, based on the available literature and their collective experience. Strategies for assessing specimen adequacy and RNA quality, maximizing tumor content, and minimizing specimen loss and RNA degradation due to pre-analytical handling are specified for small tissue and cytology specimens. By integrating current evidence and institutional insights, this review provides a practical framework for enhancing RNA-sequencing reliability and reproducibility in both clinical and research workflows.
- Open Access
mpMRI-Based Risk Estimation to Optimize Prostate Cancer Patient Selection for Active Surveillance
Background/Objectives: Active surveillance (AS) has emerged as a safe alternative to primary therapy for low- and select intermediate-risk prostate cancer (PCa), but optimal patient selection and surveillance strategies remain challenging due to limited risk stratification tools enabling early detection of lesions with high potential for histopathological progression. This study presents an integrated method for predicting prostate cancer progression within 12 months, aiming to improve AS patient selection by categorizing patients into two risk groups: rapid progressors who would benefit from immediate treatment and slow progressors suitable for AS. Methods: The risk assessment platform combines convolutional neural networks for automatic segmentation of prostate and suspicious-for-cancer lesions on multiparametric MRI (mpMRI) with logistic regression to estimate progression risk. The networks were trained on annotated lesions from radical prostatectomy specimen mapped to mpMRI. The prediction model incorporated pre-biopsy clinical variables (age, PSA, PI-RADS) and MRI-derived intratumoral radiomic features from 163 participants of a prospective clinical trial, using histopathological progression within 12 months as endpoint. Results: The clinical-radiomics model achieved an AUC of 0.84 in distinguishing rapid from slow progressors, using non-invasive monitoring techniques. In an independent test set, the model significantly improved AS patient selection, increasing negative predictive value by 18.5% compared to current standard-of-care (p < 0.001). Conclusions: The risk assessment platform shows promise for use during annual follow-up visits to reliably differentiate suitable AS candidates with stable disease from PCa patients who are likely to experience early progression.
Open AccessmpMRI-Based Risk Estimation to Optimize Prostate Cancer Patient Selection for Active Surveillance
Background/Objectives: Active surveillance (AS) has emerged as a safe alternative to primary therapy for low- and select intermediate-risk prostate cancer (PCa), but optimal patient selection and surveillance strategies remain challenging due to limited risk stratification tools enabling early detection of lesions with high potential for histopathological progression. This study presents an integrated method for predicting prostate cancer progression within 12 months, aiming to improve AS patient selection by categorizing patients into two risk groups: rapid progressors who would benefit from immediate treatment and slow progressors suitable for AS. Methods: The risk assessment platform combines convolutional neural networks for automatic segmentation of prostate and suspicious-for-cancer lesions on multiparametric MRI (mpMRI) with logistic regression to estimate progression risk. The networks were trained on annotated lesions from radical prostatectomy specimen mapped to mpMRI. The prediction model incorporated pre-biopsy clinical variables (age, PSA, PI-RADS) and MRI-derived intratumoral radiomic features from 163 participants of a prospective clinical trial, using histopathological progression within 12 months as endpoint. Results: The clinical-radiomics model achieved an AUC of 0.84 in distinguishing rapid from slow progressors, using non-invasive monitoring techniques. In an independent test set, the model significantly improved AS patient selection, increasing negative predictive value by 18.5% compared to current standard-of-care (p < 0.001). Conclusions: The risk assessment platform shows promise for use during annual follow-up visits to reliably differentiate suitable AS candidates with stable disease from PCa patients who are likely to experience early progression.
- Open Access
Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI
The utilization of multi-parametric MRI (mpMRI) in clinical decisions regarding prostate cancer patients’ management has recently increased. After biopsy, clinicians can assess risk using National Comprehensive Cancer Network (NCCN) risk stratification schema and commercially available genomic classifiers, such as Decipher. We built radiomics-based models to predict lesions/patients at low risk prior to biopsy based on an established three-tier clinical-genomic classification system. Radiomic features were extracted from regions of positive biopsies and Normally Appearing Tissues (NAT) on T2-weighted and Diffusion-weighted Imaging. Using only clinical information available prior to biopsy, five models for predicting low-risk lesions/patients were evaluated, based on: 1: Clinical variables; 2: Lesion-based radiomic features; 3: Lesion and NAT radiomics; 4: Clinical and lesion-based radiomics; and 5: Clinical, lesion and NAT radiomic features. Eighty-three mpMRI exams from 78 men were analyzed. Models 1 and 2 performed similarly (Area under the receiver operating characteristic curve were 0.835 and 0.838, respectively), but radiomics significantly improved the lesion-based performance of the model in a subset analysis of patients with a negative Digital Rectal Exam (DRE). Adding normal tissue radiomics significantly improved the performance in all cases. Similar patterns were observed on patient-level models. To the best of our knowledge, this is the first study to demonstrate that machine learning radiomics-based models can predict patients’ risk using combined clinical-genomic classification.
Open AccessClinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI
The utilization of multi-parametric MRI (mpMRI) in clinical decisions regarding prostate cancer patients’ management has recently increased. After biopsy, clinicians can assess risk using National Comprehensive Cancer Network (NCCN) risk stratification schema and commercially available genomic classifiers, such as Decipher. We built radiomics-based models to predict lesions/patients at low risk prior to biopsy based on an established three-tier clinical-genomic classification system. Radiomic features were extracted from regions of positive biopsies and Normally Appearing Tissues (NAT) on T2-weighted and Diffusion-weighted Imaging. Using only clinical information available prior to biopsy, five models for predicting low-risk lesions/patients were evaluated, based on: 1: Clinical variables; 2: Lesion-based radiomic features; 3: Lesion and NAT radiomics; 4: Clinical and lesion-based radiomics; and 5: Clinical, lesion and NAT radiomic features. Eighty-three mpMRI exams from 78 men were analyzed. Models 1 and 2 performed similarly (Area under the receiver operating characteristic curve were 0.835 and 0.838, respectively), but radiomics significantly improved the lesion-based performance of the model in a subset analysis of patients with a negative Digital Rectal Exam (DRE). Adding normal tissue radiomics significantly improved the performance in all cases. Similar patterns were observed on patient-level models. To the best of our knowledge, this is the first study to demonstrate that machine learning radiomics-based models can predict patients’ risk using combined clinical-genomic classification.
- 2 August 2023
- Published by Springer Nature
- p. 565-574
Circulating Tumor Cells in Men Treated for Prostate Cancer
- 2 August 2023
- Published by Springer Nature
- p. 565-574
Circulating Tumor Cells in Men Treated for Prostate Cancer
- Open Access
Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
We investigated the longitudinal changes in multiparametric MRI (mpMRI) (T2-weighted, Apparent Diffusion Coefficient (ADC), and Dynamic Contrast Enhanced (DCE-)MRI) of prostate cancer patients receiving Lattice Extreme Ablative Dose (LEAD) radiotherapy (RT) and the capability of their imaging features to predict RT outcome based on endpoint biopsies. Ninety-five mpMRI exams from 25 patients, acquired pre-RT and at 3-, 9-, and 24-months post-RT were analyzed. MRI/Ultrasound-fused biopsies were acquired pre- and at two-years post-RT (endpoint). Five regions of interest (ROIs) were analyzed: Gross tumor volume (GTV), normally-appearing tissue (NAT) and peritumoral volume in both peripheral (PZ) and transition (TZ) zones. Diffusion and perfusion radiomics features were extracted from mpMRI and compared before and after RT using two-tailed Student t-tests. Selected features at the four scan points and their differences (Δ radiomics) were used in multivariate logistic regression models to predict the endpoint biopsy positivity. Baseline ADC values were significantly different between GTV, NAT-PZ, and NAT-TZ (p-values < 0.005). Pharmaco-kinetic features changed significantly in the GTV at 3-month post-RT compared to baseline. Several radiomics features at baseline and three-months post-RT were significantly associated with endpoint biopsy positivity and were used to build models with high predictive power of this endpoint (AUC = 0.98 and 0.89, respectively). Our study characterized the RT-induced changes in perfusion and diffusion. Quantitative imaging features from mpMRI show promise as being predictive of endpoint biopsy positivity.
Open AccessLongitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
We investigated the longitudinal changes in multiparametric MRI (mpMRI) (T2-weighted, Apparent Diffusion Coefficient (ADC), and Dynamic Contrast Enhanced (DCE-)MRI) of prostate cancer patients receiving Lattice Extreme Ablative Dose (LEAD) radiotherapy (RT) and the capability of their imaging features to predict RT outcome based on endpoint biopsies. Ninety-five mpMRI exams from 25 patients, acquired pre-RT and at 3-, 9-, and 24-months post-RT were analyzed. MRI/Ultrasound-fused biopsies were acquired pre- and at two-years post-RT (endpoint). Five regions of interest (ROIs) were analyzed: Gross tumor volume (GTV), normally-appearing tissue (NAT) and peritumoral volume in both peripheral (PZ) and transition (TZ) zones. Diffusion and perfusion radiomics features were extracted from mpMRI and compared before and after RT using two-tailed Student t-tests. Selected features at the four scan points and their differences (Δ radiomics) were used in multivariate logistic regression models to predict the endpoint biopsy positivity. Baseline ADC values were significantly different between GTV, NAT-PZ, and NAT-TZ (p-values < 0.005). Pharmaco-kinetic features changed significantly in the GTV at 3-month post-RT compared to baseline. Several radiomics features at baseline and three-months post-RT were significantly associated with endpoint biopsy positivity and were used to build models with high predictive power of this endpoint (AUC = 0.98 and 0.89, respectively). Our study characterized the RT-induced changes in perfusion and diffusion. Quantitative imaging features from mpMRI show promise as being predictive of endpoint biopsy positivity.
- Open Access
- 30 September 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (16) , 6915-6922
Self‐Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy
Concerns about overtreatment of clinically indolent prostate cancer (PrCa) have led to recommendations that men who are diagnosed with low‐risk PrCa be managed by active surveillance (AS) rather than immediate definitive treatment. However the risk of underestimating the aggressiveness of a patient's PrCa can be a significant source of anxiety and a barrier to patient acceptance of AS. The uncertainty is particularly keen for African American (AA) men who are about 1.7 times more likely to be diagnosed with PrCa than European American (EA) men and about 2.4 times more likely to die of this disease. The AA population, as many other populations in the Americas, is genetically heterogeneous with varying degrees of admixture from West Africans (WAs), Europeans, and Native Americans (NAs). Recommendations for PrCa screening and management rarely consider potential differences in risk within the AA population. We compared WA genetic ancestry in AA men undergoing standard prostate biopsy who were diagnosed with no cancer, low‐grade PrCa (Gleason Sum 6), or higher grade PrCa (Gleason Sum 7‐10). We found that WA genetic ancestry was significantly higher in men who were diagnosed with PrCa on biopsy, compared to men who were cancer‐negative, and highest in men who were diagnosed with higher grade PrCa (Gleason Sum 7‐10). Incorporating WA ancestry into the guidelines for making decisions about when to obtain a biopsy and whether to choose AS may allow AA men to personalize their approach to PrCa screening and management.
- 30 September 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (16) , 6915-6922
Open AccessSelf‐Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy
Concerns about overtreatment of clinically indolent prostate cancer (PrCa) have led to recommendations that men who are diagnosed with low‐risk PrCa be managed by active surveillance (AS) rather than immediate definitive treatment. However the risk of underestimating the aggressiveness of a patient's PrCa can be a significant source of anxiety and a barrier to patient acceptance of AS. The uncertainty is particularly keen for African American (AA) men who are about 1.7 times more likely to be diagnosed with PrCa than European American (EA) men and about 2.4 times more likely to die of this disease. The AA population, as many other populations in the Americas, is genetically heterogeneous with varying degrees of admixture from West Africans (WAs), Europeans, and Native Americans (NAs). Recommendations for PrCa screening and management rarely consider potential differences in risk within the AA population. We compared WA genetic ancestry in AA men undergoing standard prostate biopsy who were diagnosed with no cancer, low‐grade PrCa (Gleason Sum 6), or higher grade PrCa (Gleason Sum 7‐10). We found that WA genetic ancestry was significantly higher in men who were diagnosed with PrCa on biopsy, compared to men who were cancer‐negative, and highest in men who were diagnosed with higher grade PrCa (Gleason Sum 7‐10). Incorporating WA ancestry into the guidelines for making decisions about when to obtain a biopsy and whether to choose AS may allow AA men to personalize their approach to PrCa screening and management.